These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21128849)

  • 1. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
    Dailey G; Admane K; Mercier F; Owens D
    Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
    Swinnen SG; Dain MP; Aronson R; Davies M; Gerstein HC; Pfeiffer AF; Snoek FJ; Devries JH; Hoekstra JB; Holleman F
    Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
    J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.
    Fadini GP; de Kreutzenberg SV; Mariano V; Boscaro E; Bertolini F; Mancuso P; Quarna J; Marescotti M; Agostini C; Tiengo A; Avogaro A
    Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal insulin treatment in type 2 diabetes.
    Hedrington MS; Pulliam L; Davis SN
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1(Suppl 1):S33-42. PubMed ID: 21668335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.